Eocene Ltd. (EOCN) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Eocene Ltd. (EOCN) closed at USD 3.01 on 2026-10-14, a change of -74.4 % over the past year, with a market capitalization of USD 3.26M.
Eocene Ltd. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 3.01 |
| 2026-10-13 | 3.16 |
| 2026-10-12 | 3.22 |
| 2026-10-09 | 3.54 |
| 2026-10-08 | 3.62 |
| 2026-10-07 | 3.46 |
| 2026-10-06 | 3.36 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Eocene Ltd. key figures
- Previous close
- USD 3.01 (2026-10-14)
- 1-year change
- -74.4 %
- Market cap
- USD 3.26M
- Enterprise value
- USD -8.05M
- P/E ratio (trailing)
- -0.21
- P/E ratio (forward)
- n/a
- EPS (trailing)
- -14.47
- EPS (forward)
- n/a
- PEG ratio
- n/a
- Price to book
- 0.24
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 0.43
- Employees
- 3
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Eocene Ltd.
Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Eocene Ltd. and compare it with other stocks.
Analyze EOCNAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Eocene Ltd. shares.